Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
DRUG FORMULATION CONTAINING SEPETAPROST
Document Type and Number:
WIPO Patent Application WO/2022/034909
Kind Code:
A1
Abstract:
The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.

Inventors:
YAMAMOTO YASUKO (JP)
TANIGUCHI TAKAZUMI (JP)
SHIMAZAKI ATSUSHI (JP)
KIMURA ERIKA (JP)
Application Number:
PCT/JP2021/029701
Publication Date:
February 17, 2022
Filing Date:
August 12, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SANTEN PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/558; A61K45/00; A61P27/06
Domestic Patent References:
WO2011013651A12011-02-03
WO2019131901A12019-07-04
WO2019124489A12019-06-27
WO2011013651A12011-02-03
Other References:
KAMBE, TOHRU; SUGIMOTO, ISAMU; OBITSU, TETSUO; TANI, KOUSUKE; MARUYAMA, TORU: "Discovery of Potent, Selective Prostaglandin EP 3/FP Dual Agonist, ONO-9054, for the Treatment of Glaucoma ", MEDCHEM NEWS, vol. 27, no. 2, 1 May 2017 (2017-05-01), JP, pages 70 - 77, XP009535018, ISSN: 2432-8618, DOI: 10.14894/medchem.27.2_70
AIHARA, MAKOTO: "O1-017 Intraocular Pressure Dropping Effect of Tafluprost in Low- Latanoprost-Reactivity Monkeys", NIPPON GANKA GAKKAI ZASSHI = JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 114, no. Suppl., 30 November 2008 (2008-11-30), Tokyo, JP, pages 195, XP009535222, ISSN: 0029-0203
KOCLUK YUSUF, GUNGOR KIVANC, SAYGILI OGUZHAN, BEKIR NECDET: "Efficacy of Monotherapy with Either Bimatoprost or Travoprost in Patients with Primary Open-Angle Glaucoma Resistant to Latanoprost Therapy", TURKISH JOURNAL OF OPHTHALMOLOGY, vol. 41, no. 5, 1 October 2011 (2011-10-01), Istambul, Turkey, pages 295 - 298, XP009534908, ISSN: 1300-0659, DOI: 10.4274/tjo.41.36844
OTA TAKASHI, AIHARA MAKOTO, SAEKI TADASHIRO, NARUMIYA SHUH, ARAIE MAKOTO: "The Effects of Prostaglandin Analogues on Prostanoid EP1, EP2, and EP3 Receptor-Deficient Mice", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 47, no. 8, 1 August 2006 (2006-08-01), US , pages 3395, XP055908555, ISSN: 1552-5783, DOI: 10.1167/iovs.06-0100
SHINSAKU YAMANE, TOMOHIRO KARAKAWA, SATOSHI NAKAYAMA, KAZUFUMI NAGAI, KAZUMI MORIYUKI, SHINICHI NEKI, FUMITAKA SUTO, TOHRU KAMBE, : "IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 56, no. 4, 29 April 2015 (2015-04-29), US , pages 2547 - 2552, XP055765498, ISSN: 1552-5783, DOI: 10.1167/iovs.14-16181
GEORGES KALOUCHE, FANNY BEGUIER, MICHAEL BAKRIA, STéPHANE MELIK-PARSADANIANTZ, CAROLINE LERICHE, THOMAS DEBEIR, WILLIAM ROST&: "Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells", INVESTIGATIVE OPTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 57, no. 4, 15 April 2016 (2016-04-15), US , pages 1816, XP055624516, ISSN: 1552-5783, DOI: 10.1167/iovs.15-17693
Attorney, Agent or Firm:
TSUKUNI & ASSOCIATES (JP)
Download PDF: